Point72 Hong Kong’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-4,215
Closed -$59K 1830
2022
Q3
$59K Buy
+4,215
New +$67.9K ﹤0.01% 1385
2022
Q2
Sell
-14
Closed 2528
2022
Q1
$0 Buy
+14
New +$219 ﹤0.01% 2465
2021
Q4
Sell
-1,513
Closed -$22K 2534
2021
Q3
$22K Buy
+1,513
New +$24.2K ﹤0.01% 1683
2021
Q1
Sell
-3,381
Closed -$84K 2310
2020
Q4
$84K Buy
3,381
+3,174
+1,533% +$105K ﹤0.01% 1102
2020
Q3
$9K Buy
+207
New +$9.51K ﹤0.01% 1012
2019
Q4
Sell
-143
Closed -$9K 1522
2019
Q3
$9K Buy
+143
New +$9.6K ﹤0.01% 772
2018
Q2
Sell
-440
Closed -$27K 1261
2018
Q1
$27K Buy
440
+136
+45% +$8.2K 0.01% 580
2017
Q4
$18K Sell
304
-28
-8% -$1.77K 0.01% 390
2017
Q3
$19K Buy
332
+175
+111% +$18.8K 0.01% 401
2017
Q2
$19K Sell
157
-41
-21% -$4.75K 0.02% 385
2017
Q1
$22K Buy
198
+156
+371% +$18.2K 0.03% 391
2016
Q4
$5K Buy
+42
New +$5K 0.01% 725
2016
Q2
Sell
-7
Closed -$1K 688
2016
Q1
$1K Buy
+7
New +$827 ﹤0.01% 492
2015
Q2
Sell
-107
Closed -$30K 281
2015
Q1
$30K Buy
+107
New +$23.2K 0.03% 220

Other funds holding ICPT

Point72 Hong Kong's ICPT Position: Q4 2022 in Review

Point72 Hong Kong sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q4 2022, closing a stake of 4,215 shares — an estimated $59K sold.

Point72 Hong Kong first reported a position in ICPT in Q1 2015 and held it in 14 quarters. The position peaked at $84K in Q4 2020. 144 funds tracked by Wall St. Rank hold ICPT as of Q4 2022.

  • Point72 Hong Kong reported no remaining Intercept Pharmaceuticals, Inc. position as of Q4 2022 after selling out during the quarter.
  • Point72 Hong Kong sold 4,215 Intercept Pharmaceuticals, Inc. shares in Q4 2022, an estimated $59K.
  • Point72 Hong Kong first reported a position in Intercept Pharmaceuticals, Inc. in Q1 2015 and held it in 14 quarters.
  • Point72 Hong Kong's Intercept Pharmaceuticals, Inc. position peaked at $84K in Q4 2020.
  • 144 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q4 2022.

Based on Point72 Hong Kong's 13F filing for Q4 2022, filed 14 Feb 2023.